First Malaria Vaccine Approved By WHO: The World Health Organization (WHO) approved the world’s first malaria vaccine on Wednesday. It should be given to youngsters all over Africa, according to the World Health Organization, in the hopes of reviving faltering attempts to stop the parasitic disease from spreading.
RTS,S, or Mosquirix, is a vaccine developed by GlaxoSmithKline, a British pharmaceutical company. “We are really proud of this vaccination because it was developed in Africa by African scientists,” said WHO Director-General Tedros Adhanom Ghebreyesus. – First Malaria Vaccine Approved By WHO
What is Mosquirix?
Mosquirix is a malaria vaccine that is given to children aged 6 weeks to 17 months, according to the European Medicines Agency. It also protects against hepatitis B virus infection of the liver, while the European Medicines Agency warns that the vaccination should not be administered alone for this purpose.
GlaxoSmithKline developed the vaccine in 1987. It does, however, have drawbacks: Mosquirix might take up to four doses to work, and its protection wears out after a few months.
Despite this, scientists believe the vaccine will have a significant impact on malaria in Africa. In a large-scale trial programme organised by the WHO, 2.3 million doses of Mosquirix have been given to newborns in Ghana, Kenya, and Malawi since 2019. The disease kills the majority of children under the age of five.
What is the purpose of Mosquirix?
Mosquirix is injected into a muscle in the thigh or around the shoulder in a 0.5 ml dose (the deltoid). Three shots are given to the youngster, with one month between each treatment. 18 months following the third injection, a fourth injection is advised. Mosquirix is only available with a doctor’s prescription.
What is the mechanism of Mosquirix?
The active ingredient of Mosquirix, according to European Medicines Agency scientists, is made up of proteins found on the surface of Plasmodium falciparum parasites. When given to a youngster, the immune system recognises the parasite’s ‘foreign’ proteins and produces antibodies against them.
What is Mosquirix’s effectiveness?
Although the vaccine’s effectiveness in preventing severe instances of malaria in children is only around 30%, it is the only one that has been licenced. It was approved by the European Union’s pharmaceuticals agency in 2015, with the benefits outweighing the hazards. The vaccine’s side effects are rare, according to the WHO, although they can include a fever that might lead to brief seizures.
How will Mosquirix aid in the prevention of malaria?
According to Azra Ghani, chair of infectious diseases at Imperial College London, administering the malaria vaccine to children in Africa might result in a 30% drop in overall infections, with up to 8 million fewer cases and 40,000 fewer fatalities per year. “A 30% reduction may not seem like much to folks who do not live in malaria-endemic nations. “However, malaria is a major issue for the people who live in those places,” Ghani remarked. “A 30% cut will save a lot of lives and prevent moms from taking their children to health clinics, clogging up the system.”
Africa’s Major Problem “Malaria”
Malaria is significantly more harmful in Africa than Covid-19. Pseudomonas falciparum is the parasite that causes it. According to a WHO estimate, the disease killed 386,000 Africans in 2019, compared to 212,000 confirmed fatalities from Covid-19 in the previous 18 months.
According to the WHO, Africa, which has a population of 1.3 billion people, accounts for 94% of malaria infections and fatalities. The disease is caused by parasites that are transferred to individuals by mosquito bites; symptoms include fever, vomiting, and exhaustion. – First Malaria Vaccine Approved By WHO